SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:DiVA.org:uu-403038"
 

Sökning: onr:"swepub:oai:DiVA.org:uu-403038" > Viral safety of hum...

Viral safety of human platelet lysate for cell therapy and regenerative medicine : Moving forward, yes, but without forgetting the past

Burnouf, Thierry (författare)
Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei, Taiwan;Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei, Taiwan;Taipei Med Univ, Coll Biomed Engn, Res Ctr Biomed Devices, Taipei, Taiwan;Taipei Med Univ, Coll Med, Int PhD Program Cell Therapy & Regenerat Med, Taipei, Taiwan
Barro, Lassina (författare)
Taipei Med Univ, Coll Biomed Engn, Int PhD Program Biomed Engn, Taipei, Taiwan
Nebie, Ouada (författare)
Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei, Taiwan
visa fler...
Wu, Yu-Wen (författare)
Taipei Med Univ, Coll Biomed Engn, Grad Inst Biomed Mat & Tissue Engn, Taipei, Taiwan
Goubran, Hadi (författare)
Univ Saskatchewan, Coll Med, Div Oncol, Saskatoon Canc Ctr, Saskatoon, SK, Canada
Knutson, Folke (författare)
Uppsala universitet,Klinisk immunologi,Klinisk immunologi och transfusionsmedicin
Seghatchian, Jerard (författare)
Int Consultancy Blood Components Qual Safety Impr, London, England
visa färre...
 (creator_code:org_t)
PERGAMON-ELSEVIER SCIENCE LTD, 2019
2019
Engelska.
Ingår i: Transfusion and apheresis science. - : PERGAMON-ELSEVIER SCIENCE LTD. - 1473-0502 .- 1878-1683. ; 58:6
  • Forskningsöversikt (refereegranskat)
Abstract Ämnesord
Stäng  
  • Growth factor-rich pooled human platelet lysate (HPL), made from human platelet concentrates, is one new blood-derived bioproduct that is attracting justified interest as a xeno-free supplement of growth media for human cell propagation for cell therapy. HPL can also find potentially relevant applications in the field of regenerative medicine. Therefore, the therapeutic applications of HPL go far beyond the standard clinical applications of the traditional blood products typically used in patients suffering from life-threatening congenital or acquired deficiencies in cellular components or proteins due to severe genetic diseases or trauma. A wider population of patients, suffering from various pathologies than has traditionally been the case, is thus, now susceptible to receiving a human blood-derived product. These patients would, therefore, be exposed to the possible, but avoidable, side effects of blood products, including transfusion-transmitted infections, most specifically virus transmissions. Unfortunately, not all manufacturers, suppliers, and users of HPL may have a strong background in the blood product industry. As such, they may not be fully aware of the various building blocks that should contribute to the viral safety of HPL as is already the case for any licensed blood products. The purpose of this manuscript is to reemphasize all the measures, including in regulatory aspects, capable of assuring that HPL exhibits a sufficient pathogen safety margin, especially when made from large pools of human platelet concentrates. It is vital to remember the past to avoid that the mistakes, which happened 30 to 40 years ago and led to the contamination of many blood recipients, be repeated due to negligence or ignorance of the facts.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Hematologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Hematology (hsv//eng)

Nyckelord

Human platelet lysate
Virus
Safety
HPL

Publikations- och innehållstyp

ref (ämneskategori)
for (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy